Successful treatment with intravenous immunoglobulins in a patient affected by dermatomyositis/systemic lupus erythematosus overlap syndrome and tuberculosis

Clinical Immunology

Volumn 125, Issue 2, 2007, Pages 127-130

  Luzi, Giuseppe ^a   Diamanti, Andrea Picchianti ^a   Germano, Valentina ^a   Laganà, Bruno ^a   Di Rosa, Roberta ^a   Salemi, Simonetta ^a   Stoppacciaro, Antonella ^a   D'Amelio, Raffaele ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

DM; IVIG; SLE; TB

Indexed keywords

ANTINUCLEAR ANTIBODY; IMMUNOGLOBULIN; ISONIAZID; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN; STEROID; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; ISONIAZID; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS;

EID: 35248862123     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.07.009     Document Type: Article

References (17)

1. Dalakas M.C. Polymyositis, dermatomyositis, and inclusion body myositis. Harrison's Principles of Internal Medicine. 16th edition (2005), McGraw-Hill Medical Publishing Division 2540-2545
2. Patel S.Y., and Kumararatne D.S. From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies. Clin. Exp. Immunol. 124 (2001) 169-174
3. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of SLE. Arthritis Rheum. 40 (1997) 1725
4. Zaidan R., Al Moallem M., Wani B.A., Shameena A.R., Al Tahan A.R., Daif A.K., and Al Rajeh S. Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur. J. Neurol. 10 (2003) 367-372
5. Christen U., and von Herrath M.G. Infections and autoimmunity-Good or bad?. J. Immunol. 174 (2005) 7481-7486
6. Sekigawa I., Nawata M., Seta N., Yamada M., Iidia N., and Hashimoto H. Cytomegalovirus infection in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 20 (2002) 559-564
7. Marie I., Hachulla E., Chérin P., Hellot M.F., Herson S., Levesque H., and Hatron P.Y. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum. 53 (2005) 155-165
8. Kim H.A., Yoo C.D., Baek H.J., Lee E.B., Ahn C., Han J.S., Kim S., Lee J.S., Choe K.W., and Song Y.W. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin. Exp. Rheumatol. 16 (1998) 9-13
9. Hernandez-Cruz B., Sifuentes-Osornio J., Ponce de Leon R.S., Ponce de Leon G., and Diaz-Jouanen E. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case series. Clin. Exp. Rheumatol. 17 (1999) 289-296
10. Marie I., Hachulla E., Hatron P.Y., et al. Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J. Rheumatol. 28 (2001) 2230-2237
11. Roy E., Stravopoulos E., Brennan J., Coade S., Grigorieva E., Walzer B., Dagg B., Tascon R.E., Lowrie D.B., Colston M.J., and Jolles S. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium Tuberculosis infection in mice. Infect. Immun. 10 (2005) 6101-6109
12. Toubi E., Kessel A., and Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum. Immunol. 66 (2005) 395-402
13. Huang H.-C., YU W.-L., Sheid C.-C., Cheng K.-C., and Cheng H.-H. Unusual mixed infection of thoracic empyema caused by Mycobacteria tuberculosis, Non tuberculosis mycobacteria and Nocardia asteroides in a woman with systemic lupus erythematosus. J. Infect. 54 (2007) 25-28
14. Saito M., Saito Y., Endo K., and Tanaka M. A case of steroid-resistant polymyositis who made a good response to high dose intravenous immunoglobulins (IVIG). Rinsho Shinkeigaku 40 (2000) 181-183
15. Siegel J. The product: all intravenous immunoglobulins are not equivalent. Pharmacotherapy 25 11Pt2 (2005) 78S-84S
16. Gelfand E.W. Differences between IVIG products: impact on clinical outcome. Int. Immunopharmacol. 6 (2006) 592-599
17. Andonopoulos A.P., Safridi C., Karokis D., and Bounas A. Is a purified protein derivative skin test and subsequent antituberculous chemoprophylaxis really necessary in systemic rheumatic disease patients receiving corticosteroids?. Clin. Rheumatol. 17 (1998) 181-185